158 related articles for article (PubMed ID: 25552351)
1. Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.
Jallad RS; Trarbach EB; Duarte FH; Jorge AA; Bronstein MD
Pituitary; 2015 Oct; 18(5):666-73. PubMed ID: 25552351
[TBL] [Abstract][Full Text] [Related]
2. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
[TBL] [Abstract][Full Text] [Related]
3. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
4. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.
Ramos-Leví AM; Marazuela M; Paniagua A; Quinteiro C; Riveiro J; Álvarez-Escolá C; Lúcas T; Blanco C; de Miguel P; Martínez de Icaya P; Pavón I; Bernabeu I
Eur J Endocrinol; 2015 Feb; 172(2):115-22. PubMed ID: 25385818
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.
Mercado M; González B; Sandoval C; Esquenazi Y; Mier F; Vargas G; de los Monteros AL; Sosa E
J Clin Endocrinol Metab; 2008 Sep; 93(9):3411-5. PubMed ID: 18611972
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
[TBL] [Abstract][Full Text] [Related]
7. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
Ballerini MG; Domené HM; Scaglia P; Martínez A; Keselman A; Jasper HG; Ropelato MG
Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
[TBL] [Abstract][Full Text] [Related]
8. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
9. Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.
Topsakal S; Akin F; Turgut S; Yerlikaya E; Yaylali GF
Adv Clin Exp Med; 2017; 26(2):281-286. PubMed ID: 28791847
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
12. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
13. GH receptor isoforms and skeletal fragility in acromegaly.
Mormando M; Nasto LA; Bianchi A; Mazziotti G; Giampietro A; Pola E; Pontecorvi A; Giustina A; De Marinis L
Eur J Endocrinol; 2014 Aug; 171(2):237-45. PubMed ID: 24866575
[TBL] [Abstract][Full Text] [Related]
14. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
16. Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.
Pontes J; Madeira M; Lima CHA; Ogino LL; de Paula Paranhos Neto F; de Mendonça LMC; Farias MLF; Kasuki L; Gadelha MR
J Endocrinol Invest; 2020 Feb; 43(2):163-171. PubMed ID: 31392573
[TBL] [Abstract][Full Text] [Related]
17. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
[TBL] [Abstract][Full Text] [Related]
18. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
[TBL] [Abstract][Full Text] [Related]
20. Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene.
Gao M; Zhu B; Xu Z; Liu S; Liu J; Zhang G; Gao Y; Fan Y; Kang X
BMC Med Genet; 2018 Oct; 19(1):182. PubMed ID: 30290787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
